About Senti Biosciences
Senti Biosciences is a publicly listed company based in San Francisco (United States) founded in 2016 by Jim Collins, Wilson Wong, and Tim Lu. Cell-based therapies for cancer treatment are developed. Senti Biosciences has raised $158 million across 8 funding rounds from investors including Amgen, ARE and Mirae Asset. The company has 34 employees. Its chief executive, as recorded, is Tim Lu. Its website sentibio.com draws about 20 thousand monthly visits. Senti Biosciences offers products and services including SENTI-202, SENTI-301A, and Gene Circuits Platform. Its focus areas include Life Sciences, Genomics, Enabling Technologies and Technology Platforms. Its legal entity is SENTI BIOSCIENCES, INC. Its competitors include Caribou Biosciences, Poseida Therapeutics and Tenaya Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Senti Biosciences was founded in 2016 and is headquartered in San Francisco, United States. A proprietary synthetic biology platform is utilized to engineer cell and gene therapies targeted at cancer. Therapeutic gene circuits are optimized for diverse applications in oncology. CAR-NK-based treatments are provided for various cancers and tumors, supporting advancements in the biotechnology sector.
- Headquarters San Francisco, United States
- Employees 34
- Founders Jim Collins, Wilson Wong, Tim Lu
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website sentibio.com
- Social LinkedIn X
- Legal Name Senti Biosciences, Inc.
- Annual Revenue$22 K (USD)as on Dec 31, 2025
- Net Profit-$61.44 M (USD)-16.38as on Dec 31, 2025
- EBITDA-$60.09 M (USD)-9.5as on Dec 31, 2025
- Total Equity Funding$158M (USD)
in 8 rounds
- Latest Funding Round$40M (USD), Post-IPO
May 2026
- InvestorsAmgen
& 26 more
- Employee Count34
Products & Services of Senti Biosciences
Senti Biosciences offers a comprehensive portfolio of products and services, including SENTI-202, SENTI-301A, and Gene Circuits Platform.
Targets acute myeloid leukemia using off-the-shelf NK cells.
Treats hepatocellular carcinoma through engineered cell therapies.
Reprograms cells to sense and respond in cancer treatment applications.
Funding Insights of Senti Biosciences
Senti Biosciences has successfully raised a total of $158M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $158M
- Total Rounds 8
- Last Round Post-IPO — $40M
- First Round $225,000
(Jan 2018)
- Investors Count 27
All 8 funding rounds of Senti Biosciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2026 | $40M | Post-IPO | – | – | |
| Dec 2024 | $10M | Post-IPO | – | Celadon Partners | |
| Dec 2024 | $37.6M | Post-IPO | – | Celadon Partners | |
| Jun 2024 | $8M | Grant | – | – | |
| Jan 2021 | $105M | Series B | – | Leaps by Bayer | |
| Sep 2018 | $225,000 | Grant | – | – | |
| Feb 2018 | $53M | Series A | – | New Enterprise Associates | |
| Jan 2018 | $225,000 | Grant | – | – |
27 investors in total: 27 institutional.
Investors in Senti Biosciences
Senti Biosciences has secured backing from 27 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, ARE and Mirae Asset.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| celadonpartners.com | ||||
Venture capital investments are offered to startups by NEA. | nea.com | Menlo Park, United States | ||
Venture capital firm investing in life sciences sector | leaps.bayer.com | Leverkusen, Germany | ||
Multiple sectors are invested in by this venture capital firm. | matrixpartners.com.cn | Chaoyang, China | ||
Ridgeback Capital is focused on healthcare and life science investments. | ridgebackcap.com | New York, United States | ||
Seed and early-stage technology companies are funded by Lux Capital. | luxcapital.com | Menlo Park, United States | ||
Venture capital investing with a focus on diversity and inclusion in the ecosystem. | gaingels.com | |||
Venture capital fund investing in early-stage tech startups | 1990 | kbic.co.kr | Seoul, South Korea | |
Venture capital firm focused on healthcare startups | lifeforcecap.com | San Francisco, United States | ||
Private equity firm investing in multiple sectors | noveus.vc | San Francisco, United States |
Investor details for Senti Biosciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Senti Biosciences
43 people are tracked at Senti Biosciences (17 in leadership, 11 in board & advisors, 15 in team); the tracked headcount is 34.
| Name | Role | Group |
|---|---|---|
Jim Collins | Co-Founder | Leadership |
Wilson Wong | Co-Founder | Leadership |
Tim Lu | Co-Founder & CEO | Leadership |
Thomas Chung | Vice President, Strategic Finance & Corporate Development | Leadership |
Brian Garrison | Vice President Of Research | Leadership |
Kojo Dwumfuoh | Associate Director, QA Validation | Leadership |
Kanya Rajangam | President, Head Of Research & Development And Chief Medical Officer | Leadership |
Nick Frankel | Interim Head, Analytical Development (current) | Leadership |
Eric Allen | Senior Director, Financial Controller | Leadership |
Aaron N. Nguyen | Senior Director, Translational Research | Leadership |
Rochelle Emery M.D. | Medical Director | Leadership |
Amy Alford, MA | Vice President, Research & Development Operations | Leadership |
Nikul Patel | Senior Director, Process Development | Leadership |
Yvonne Li | Interim Chief Financial Officer | Leadership |
Faraz Siddiqui | Senior Vice President, Technical Operations | Leadership |
Dee Olomajeye | Vice President, People Strategy And Administrative Operations | Leadership |
Rob Cutler | SVP - Head Of Legal Affairs | Leadership |
Robin G. Taylor | Board Member | Board & advisors |
James Collins | Co-Founder & Chairperson | Board & advisors |
Martin Fussenegger | Board Member | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for Senti Biosciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Senti Biosciences
Senti Biosciences is a publicly listed company on the NASDAQ with ticker symbol SNTI in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Sep 2021
- Listed onNASDAQ: SNTI
- Listed entitySenti Biosciences, Inc.
- Exchange sectorHealth technology
- ISINUS8169441024
- Share price$0.26 (-19.96% on the day) · 2026-10-13
- Market capitalisation$7.9M
- EPS (diluted, trailing year)$-1.77
- Volume (last session)302,824
Financials of Senti Biosciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $22,000 | -$61.4M | -$60.1M |
| 2024 | -$52.8M | -$54.9M | |
| 2023 | $2.6M | -$92.9M | -$61.5M |
| 2022 | $4.3M | -$58.2M | -$58.2M |
| 2021 | $2.8M | -$55.3M | -$37.4M |
Detailed financial statements for Senti Biosciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Senti Biosciences
4 dated milestones of Senti Biosciences across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Senti Biosciences is founded.
- Funding First funding round of $225K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $40.0M.
Competitors of Senti Biosciences
Senti Biosciences has 3 listed competitors in our database, 3 of them funded. They include Caribou Biosciences, Poseida Therapeutics and Tenaya Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions | |
| poseida.com | 2015 | San Diego, United States | $323.78M | 259 | Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies | |
| tenayatherapeutics.com | 2016 | San Francisco, United States | $142M | 140 | Regenerative and gene therapeutics for heart failure are developed. |
Detailed competitors of Senti Biosciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Senti Biosciences
The website of Senti Biosciences (sentibio.com) receives about 19.6K visits a month and ranks #2,633,040 among all websites worldwide, #3,594 in Biotechnology and Pharmaceuticals.
- Monthly visits19.6K
▲ 156.3% vs previous month
- Unique visitors3.5K
per month
- Global rank#2,633,040
among all websites
- Category rank#3,594
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.0
- Average visit46 sec
- DevicesDesktop 53% · Mobile 47%
Websites whose visitors overlap most with Senti Biosciences. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
firstwordpharma.com | firstwordpharma.com | 100% | #237,108 | – |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Senti Biosciences (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Senti Biosciences
Complete news archive for Senti Biosciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Senti Biosciences
Senti Biosciences was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Senti Biosciences is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Tim Lu is the CEO of Senti Biosciences, as recorded in our data. They have also founded this company.
Senti Biosciences is a funded company, having raised a total of $158M across 8 funding rounds to date. The company's 1st funding round was a Grant of $225K, raised on Jan 2018.
Senti Biosciences has 34 employees.
Annual revenue of Senti Biosciences is $22K as on Dec 31, 2025.
Senti Biosciences was founded in 2016 and is headquartered in San Francisco, United States. A proprietary synthetic biology platform is utilized to engineer cell and gene therapies targeted at cancer. Therapeutic gene circuits are optimized for diverse applications in oncology. CAR-NK-based treatments are provided for various cancers and tumors, supporting advancements in the biotechnology sector.
Senti Biosciences's top competitors include Caribou Biosciences, Poseida Therapeutics and Tenaya Therapeutics.
Senti Biosciences offers SENTI-202, SENTI-301A, and Gene Circuits Platform.
Yes, Senti Biosciences is publicly traded on NASDAQ under the ticker symbol SNTI.
Senti Biosciences has 27 investors. Key investors include Amgen, ARE, Mirae Asset, HHS, and Allen & Company.
Senti Biosciences operates through Senti Biosciences, Inc..